Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Histologically or cytologically confirmed endometrial (endometrioid, uterine, papillary serous carcinoma, and carcinosarcoma), ovarian (primary peritoneal/fallopian tube, serous, endometrioid, mixed, and poorly differentiated epithelial ovarian cancers \[for purposes of eligibility, carcinosarcoma is considered a poorly differentiated carcinoma\]), hepatocellular carcinoma, carcinoid or islet cell (neuroendocrine: well- or moderately-differentiated neuroendocrine) cancer which are locally advanced, recurrent, or metastatic

Patients must have measurable disease; patients having only lesions measuring \>= 1 cm to \< 2 cm must use spiral computed tomography (CT) imaging for both pre- and post-treatment tumor assessments; patients who have had prior palliative radiotherapy to metastatic lesion(s) must have at least one measurable lesion(s) that have not been previously irradiated

Radiation therapy (adjuvant or palliative) must be completed \>= 4 weeks prior to registration, if applicable

Absolute neutrophil count (ANC) \>= 1500/mm\^3

Platelets \>= 75,000/mm\^3

Hemoglobin \>= 9.0 g/dL

Total bilirubin =\< 1.5 x upper limit of normal (ULN); Note: direct bilirubin and international normalized ratio (INR) for hepatocellular carcinoma (HCC) patients allowed as per Child-Turcotte-Pugh scoring

Alkaline phosphatase =\< 2.5 x ULN (=\< 5 x ULN if liver metastasis is present or patient is in HCC cohort)

Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) =\< 2.5 x ULN (=\< 5 x ULN if liver metastasis is present or patient is in HCC cohort)

Creatinine =\<1.5 x ULN

Urinalysis \< 2+ protein; urine protein should be screened by dipstick or urine analysis; for proteinuria \>= 2+, 24-hour urine protein should be obtained and the level should be \< 2 g for patient enrollment

Fasting serum cholesterol =\< 350 mg/dL (=\< 9.0 mmol/L)

Triglycerides =\< 1.5 x ULN (mg/dL or mmol/L); patients with triglyceride levels \> 1.5 x ULN can be started on lipid lowering agents and reevaluated within 1 week; if levels go to =\< 1.5 x ULN, they can be considered for the trial and continue the lipid lowering agents; NOTE: cholesterol and triglyceride measurement and management are not required for single-agent bevacizumab cohort with islet cell carcinoma

International normalized ratio (INR) =\< 1.5 (unless the patient is on full dose warfarin)

Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1

Capable of understanding the investigational nature, potential risks and benefits of the study and able to provide valid informed consent

Negative serum pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only; NOTE: patients and their partners should be practicing an effective form of contraception during the study and for at least 3 months following the last dose of this combined therapy

Full-dose anticoagulants, if a patient is receiving full-dose anticoagulants (except carcinoid tumors), the following criteria should be met for enrollment: the subject must have an in-range INR (usually between 2 and 3) on a stable dose of warfarin or on stable dose of low molecular weight (LMW) heparin

Prior systemic treatments for metastatic disease are permitted, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy; exception: in the case of endometrial cancer no prior chemotherapy for metastatic or recurrent disease is allowed; prior planned adjuvant chemotherapy is allowed

Patients who have had prior anthracycline must have a normal ejection fraction on left ventricular ejection fraction (LVEF) assessment by multigated acquisition scan (MUGA) or echocardiogram (Echo) =\< 4 weeks prior to registration

Availability of tissue if applicable (from the primary tumor or metastases) for tumor studies for banking; Note: in the case of hepatocellular cancer if diagnosed by clinical and radiologic criteria only, availability of tissue not applicable

Willingness to donate blood for biomarker studies related to the type of therapies used in this trial and the tumor types being treated

ENDOMETRIAL CANCER (PERMANENTLY CLOSED TO ENROLLMENT)

Any hormonal therapy directed at the malignant tumor is allowed; NOTE: therapy must be discontinued at least one week prior to registration

Prior systemic therapy including biologic and immunologic agents as adjuvant treatment, must be discontinued at least 3 weeks prior to registration

Recurrent or persistent endometrial adenocarcinoma, uterine papillary serous carcinoma and carcinosarcoma which is refractory to curative therapy or established treatments; NOTE: histologic or cytologic confirmation of original primary tumor is required

HEPATOCELLULAR CANCER (PERMANENTLY CLOSED TO ENROLLMENT)

HCC confirmed by biopsy OR diagnosed by clinical and radiologic criteria; all of the following criteria must be met or a biopsy is required:

* Known cirrhosis or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

* Hypervascular liver masses \> 2 cm, and either serum alpha-fetoprotein (AFP) \> 400 ng/ml, or

* AFP \> three times normal and doubling in value in the antecedent 3 months

Child-Pugh A (=\< 6 points) or better liver status

Prior regional treatments for liver metastasis are permitted including:

* Selective internal radiation therapy such as brachytherapy, cyberknife, radiolabeled microsphere embolization, etc.

* Hepatic artery chemoembolization

* Hepatic artery embolization

* Hepatic artery infusional chemotherapy

* Radiofrequency ablation NOTE: patients must be \>= 4 weeks from treatment and show progressive disease in the liver after regional therapy or must have measurable disease outside the liver

Concomitant anti-viral therapy is allowed

History of prior varices or evidence of varices on pre-study CT/magnetic resonance imaging (MRI) imaging are required to undergo endoscopy =\< 4 weeks prior to registration; those who had received specific therapy (banding and/or sclerotherapy) and had not bled within the prior 6 months are eligible

Suitably recovered from prior localized therapy, in the opinion of the investigator

ISLET CELL CANCER AND CARCINOID TUMOR (PERMANENTLY CLOSED TO ENROLLMENT)

Patient has evidence of progressive disease as documented by Response Evaluation Criteria in Solid Tumors (RECIST) =\< 7 months prior to study entry

Carcinoid tumor cohort: prior and concurrent long-acting somatostatin analogue therapy is required; patient has to be on a stable dose of a long-acting somatostatin analogue \>= 2 months prior to study entry with documentation of progressive disease on current dose

Islet cell tumor cohort: prior and/or concurrent long-acting somatostatin analogue therapy is allowed, but not required; if patient is continued on a long-acting somatostatin analogue, a stable dose for \>= 2 months prior to study entry is required with documentation of progressive disease on current dose

Prior therapies allowed include:

* =\< 2 prior chemotherapy regimens

* Prior interferon \>= 4 weeks prior to registration

* Radiolabeled octreotide therapy (patients with prior radiolabeled octreotide therapy should have progressive disease after such therapy)

* Other investigational therapy NOTE: islet Cell Single Agent Bevacizumab Cohort: Prior mammalian target of rapamycin (mTOR) inhibitor is allowed

Prior regional treatments for liver metastasis are permitted including:

* Selective internal radiation therapy such as brachytherapy, cyberknife, radiolabeled microsphere embolization, etc.

* Hepatic artery chemoembolization

* Hepatic artery embolization

* Hepatic artery infusional chemotherapy

* Radiofrequency ablation NOTE: patients must be \>= 12 weeks from treatment and show progressive disease in the liver after regional therapy or must have measurable disease outside the liver

What this study is about